Abstract: The invention relates to a composition for the release of an active ingredient, comprising a porous matrix, a filled carrier in the matrix and the active ingredient in the carrier. The invention is suitable for the treatment of bone cancers.

Abstract: Emulsome compositions comprising phosphatidylcholine, cholesterol, tristearin, and one or more lipophilic bioactive agents such as vinpocetine are provided. The emulsomes may further comprise surface modifications of either [N-(carbonyl-methoxypropylethyleneglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, sodium salt] (MPEG-DSPE) for peglyation or stearylamine for cationization. Methods of improving brain delivery of lipophilic bioactive agents by intranasally administering such emulsome compositions are also provided.

Abstract: According to the present invention there is provided a polymer comprising at least one antiseptic/analgesic/anti-inflammatory monomeric unit in conjunction with at least three further monomeric units, said three further monomeric units eliciting properties selected from the group consisting of: temperature activation, water solubility, mechanical strength, protein/polysaccharide bonding capacity, and combinations thereof. In particular, disclosed herein is a polymer, wherein: the water-soluble monomeric unit is a hydrophilic ethylene glycol (OEGMA) moiety; the mechanical strength-conferring monomeric unit is polylactide-co-2-hydroxy-ethyl-methyl acrylate (PLA/HEMA); the protein-reactive monomeric unit is an N-acryloxysuccinimide (NAS) moiety; and the thermosetting monomeric unit is an N-isopropyl acrylamide (NIPAAm) moiety. The anti-septic/analgesic/anti-inflammatory monomeric unit comprises a methacrylic ester derivative of salicylic acid (5-HMA or 4-HMA, or a combination thereof).

Abstract: In crop production in the fields of agriculture, horticulture and the like, the damage caused by insect pests etc. is still immense, and insect pests resistant to existing insecticides have emerged. To solve the problems, the present invention has been made, and an object of the present invention is to develop and provide a novel agricultural and horticultural insecticide. The present invention provides a heterocycle-bound condensed heterocyclic compound represented by the general formula (1): {wherein R1 represents an ethyl group, R2 represents a haloalkyl group, A1 represents a N-methyl group, A2 and A3 represent a nitrogen atom, n represents 1, m represents 2, and Q represents an oxadiazole}, or a salt thereof; an agricultural and horticultural insecticide comprising the compound or a salt thereof as an active ingredient; and a method for using the insecticide.

Abstract: The present invention relates to hair care compositions comprising malodor reduction compositions and methods of using such hair care compositions. Such hair care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesirable scent and when perfume is used to scent such compositions, such scent is not unduly altered by the malodor control technology.

Abstract: The present invention relates to hair care compositions comprising malodor reduction compositions and methods of using such hair care compositions. Such hair care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesirable scent and when perfume is used to scent such compositions, such scent is not unduly altered by the malodor control technology.

Abstract: The use of a granular material which is for orally fast disintegrating tablets and comprises starch and tannic acid allows provision of tablets that can be produced by a simple process with general-purpose production equipment, disintegrate fast and absorbs water in the mouth, and have a proper level of shape retainability for practical use. The present invention also provides a method for producing an orally fast disintegrating tablet, the method comprising compression molding of a granular material for orally fast disintegrating tablets comprising starch and tannic acid, or a mixture of the granular material for orally fast disintegrating tablets and other ingredients (an additive, an active ingredient, and/or the like).

Abstract: The present invention relates to a composition for preventing or treating hearing loss, containing an HMG-CoA reductase inhibitor and, more specifically, to a composition for preventing or treating diabetes-mediated hearing loss, containing, as an active ingredient(s), one or more types selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. A pharmaceutical composition containing an HMG-CoA reductase inhibitor, according to the present invention, inhibits auditory cell death caused by diabetes, and thus is very useful as an agent for preventing or treating diabetes-mediated sensorineural hearing loss.

Abstract: This invention relates to a hair care composition which provides the desired anti-dandruff efficacy with uniform deposition of the active materials on hair/scalp. This is achieved through a judicious combination of a specific cationic deposition polymer and selective anti-dandruff agent of the right particle size.

Abstract: The present invention provides an aqueous patch which can stably contain only one of an S-enantiomer and an R-enantiomer of a drug capable of being present in such enantiomers at a relatively high concentration over a long period of time, has the excellent adhesive property and the excellent shape retaining property, and achieves high skin permeability of the drug. Specifically, the present invention provides an aqueous patch containing only one of enantiomers of a drug as an active ingredient in a pasty preparation.

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth.

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

Abstract: In various embodiments, the present invention is directed to oral pharmaceutical compositions. For example, in some embodiments, the present invention is directed to taste-masked compositions. In some embodiments, the taste masked compositions comprise a highly water soluble drug such as amphetamine, e.g., in the form of a salt such as amphetamine sulfate. In various embodiments, the present invention is directed to taste-masked, orally disintegrating compositions.

Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, gastric motility, and volume and viscosity of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects.

Abstract: The present disclosure relates to a cosmetic composition containing an oil mixture in a total amount of from about 40 to about 99% by weight, in relation to the total amount of the cosmetic composition, without taking into consideration any propellant possibly provided, wherein the oil mixture of at least two selected esters, at least one linear polydimethylsiloxane with a viscosity of from about 1 to less than about 20 cSt, also PPG-14 butyl ether, wherein cyclic polydimethylsiloxanes are contained in a total amount, in relation to the total amount of the cosmetic composition, of from 0 to about 0.4% by weight, and wherein PPG-14 butyl ether and linear polydimethylsiloxanes are contained in selected ratios by weight to one another.

Abstract: A topical supplement composition. The topical supplement composition includes one or more vitamins, minerals, or other nutrients, in combination with one or more suitable transdermal carriers. The topical supplement composition delivers vitamins, minerals or other nutrients via transdermal application from an individual's skin to the individual's bloodstream.

Abstract: The present disclosure provides compositions comprising phosphate salts having low levels of aluminum, as well as other elemental impurities. In general, phosphate salts compositions disclosed herein are liquid compositions (e.g., admixtures, solutions) comprising in situ formed phosphate salts, a pharmaceutically acceptable carrier, and less than about 250 ?g/L of aluminum. Phosphate salts solutions disclosed herein are stable over time (e.g., the amount of total phosphorus and/or the ratio of phosphate salts and/or the level of aluminum does not substantially vary, and the compositions remain free of visible particulate matter). The compositions do not require storage at less than ambient (room) temperature, i.e., no refrigeration is needed. Also provided herein are methods and systems for preparing in situ phosphate salts compositions, and methods of using phosphate salt compositions to provide phosphorous to individuals in need thereof.

Abstract: Provided herein is a personal care composition that can exhibit an increased vapor release while maintaining physical stability and texture. The personal care composition can have from about 35% to about 90% petrolatum, an additional microcrystalline wax having a needle penetration at 25° C. of from about 35 to about 75 dmm, from about 1% to about 8% of a gelling agent mixture, and from about 20% to about 50% of an olfactory composition, all by weight of the composition.